[ CAS No. 37599-58-9 ] {[proInfo.proName]}

Name: 37599-58-9|(1H-Pyrazol-3-yl)methanamine|97%
Brand: Ambeed
SKU: A136013
Rating: 98 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 37599-58-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 37599-58-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 37599-58-9 ]

SDS Specification

Alternatived Products of [ 37599-58-9 ]

Product Details of [ 37599-58-9 ]

CAS No. :	37599-58-9	MDL No. :	MFCD03422532
Formula :	C₄H₇N₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	IYSPNYLFKSTATA-UHFFFAOYSA-N
M.W :	97.12	Pubchem ID :	7147653
Synonyms :

Calculated chemistry of [ 37599-58-9 ]

Physicochemical Properties

Num. heavy atoms :	7
Num. arom. heavy atoms :	5
Fraction Csp3 :	0.25
Num. rotatable bonds :	1
Num. H-bond acceptors :	2.0
Num. H-bond donors :	2.0
Molar Refractivity :	26.26
TPSA :	54.7 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.52 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.42
Log Po/w (XLOGP3) :	-0.89
Log Po/w (WLOGP) :	-0.28
Log Po/w (MLOGP) :	-0.94
Log Po/w (SILICOS-IT) :	0.66
Consensus Log Po/w :	-0.21

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-0.34
Solubility :	44.0 mg/ml ; 0.453 mol/l
Class :	Very soluble
Log S (Ali) :	0.22
Solubility :	163.0 mg/ml ; 1.67 mol/l
Class :	Highly soluble
Log S (SILICOS-IT) :	-1.2
Solubility :	6.17 mg/ml ; 0.0635 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.21

Safety of [ 37599-58-9 ]

Signal Word:	Danger	Class:	8
Precautionary Statements:	P264-P270-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P310-P330-P331-P363-P403+P233-P501	UN#:	3259
Hazard Statements:	H302-H314	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 37599-58-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 37599-58-9 ]
Downstream synthetic route of [ 37599-58-9 ]

[ 37599-58-9 ] Synthesis Path-Upstream 1~1

1
[ 89179-62-4 ]
[ 612511-81-6 ]
[ 37599-58-9 ]

Reference： [1] Patent: WO2003/82861, 2003, A2, . Location in patent: Page/Page column 50-51

[ 37599-58-9 ] Synthesis Path-Downstream 1~19

2
[ 89179-62-4 ]
[ 612511-81-6 ]
[ 37599-58-9 ]

Yield	Reaction Conditions	Operation in experiment
		Description 30; (1-Methvl-pvrazole-3-methanamine) A solution of Description 29 (0.08g) in anhydrous tetrahydrofuran (5ml) was treated with a 1 M solution of borane/tetrahydrofuran complex in tetrahydrofuran (3. 5mi) and the mixture was heated at 65°C for 18hrs. On cooling the mixture was cautiously quenched by dropwise addition of methanol followed by 2N hydrochloric acid. The solvents were removed by evaporation, and the residue was made basic with triethylamine and concentrated in vacuo. The mixture was dissolved in a small volume of methanol applied onto a sulphonic acid SCX ion exchange cartridge (10g), eluting with methanol followed by 10percent 0. 880 ammonia in methanol. The basic fraction was evaporated in vacuo to give the title compound (0.054g) as a colourless oil which also contained-10percent of 1 H- pyrazole-3-methanamine [CAS No. 37599-58-9]. 1H nmr (D4MeOH), No. 3. 84 (2H, s, CH2) ; 3. 86 (3H, s, Me); 6.28 (1H , m, Ar); 7.53 (1H, m, Ar).

Reference： [1]Patent: WO2003/82861,2003,A2 .Location in patent: Page/Page column 50-51

3
[ 1161500-80-6 ]
[ 37599-58-9 ]
[ 1208067-87-1 ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In tetrahydrofuran; at 20℃;	A solution of 400 mg of 3-[{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-(methylsulphonyl)amino]benzoic acid, 55 mg of 1-hydroxybenzotriazole, 0.113 cm3 of triethylamine and 213 mg of 1-(3-dimethylaminopropsyl)-3-ethylcarbodiimide hydrochloride in tetrahydrofuran is admixed dropwise with 77 mg of <strong>[37599-58-9]1H-pyrazol-3-ylmethylamine</strong>. The reaction mixture is stirred overnight at a temperature in the region of 20 C. before being concentrated to dryness under reduced pressure. The residue is purified by flash chromatography on a column of 30 g of silica (Merck; elution gradient: dichloromethane/methanol 100/0 to 96/4). Concentration of the fractions under reduced pressure gives 390 mg of 3-[{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methylsulphonyl)amino]-N-(1H-pyrazol-3-ylmethyl)benzamide in the form of white crystals. m.p.: 224 C. 1H NMR spectrum (400 MHz; (delta in ppm); (DMSO-d6); referenced at 2.50 ppm): 2.70 (m, 2H); 2.96 (s, 3H); 3.33 (m, 2H); 4.37 (s, 1H); 4.47 (extended m, 2H); 4.72 (m, 1H); 6.16 (broad s, 1H); 7.30 (d, J=8.7 Hz, 4H); 7.35 (d, J=8.7 Hz, 4H); 7.44-7.67 (m, 3H); 7.79 (broad s, 1H); 7.86 (m, 1H); 8.96 (extended m, 1H); 12.57 (extended m, 1H) Mass spectrum: ES m/z=584 ([M+H]+, base peak); m/z=350 [M+H-C13H8Cl2]+

Reference： [1]Patent: US2011/152236,2011,A1 .Location in patent: Page/Page column 5

4
(R)-2-(2-(1H-indol-4-yl)-6a,7,9,10-tetrahydro-[1,4]oxazino[3,4-h]pteridin-5(6H)-yl)acetic acid hydrochloride [ No CAS ]
[ 37599-58-9 ]
[ 1394072-87-7 ]

Yield	Reaction Conditions	Operation in experiment
52.6%	With triethylamine; HATU; In N,N-dimethyl-formamide; at 20℃; for 1h;	Example 72 (R)-2-(2-(1H-indol-4-yl)-6a,7,9,10-tetrahydro-[1,4]oxazino[3,4-h]pteridin-5(6H)-yl)-N-((1H-pyrazol-3-yl)methyl)acetamide To a mixture of (R)-2-(2-(1H-indol-4-yl)-6a,7,9,10-tetrahydro-[1,4]oxazino[3,4-h]pteridin-5(6H)-yl)acetic acid, HCl (60 mg, 0.149 mmol), <strong>[37599-58-9]1H-pyrazol-3-ylmethylamine</strong> (21.75 mg, 0.224 mmol) and Et3N (0.062 mL, 0.448 mmol) in DMF (1 mL) was added HATU (73.8 mg, 0.194 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour and was subsequently diluted with EtOAc, washed with aqueous saturated NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2-NH, 0-10% MeOH/CHCl3 gradient) to give the title compound as an off-white solid (34.9 mg, 52.6% yield). 1H NMR (400 MHz, DMSO-d6) delta 3.02 (s, 1H), 3.14-3.42 (m, 3H), 3.51-3.72 (m, 2H), 3.80-3.95 (m, 2H), 4.02-4.14 (m, 2H), 4.31 (m, J=5.05 Hz, 2H), 4.49-4.59 (m, 1H), 6.14 (br s, 1H), 7.12 (t, J=7.83 Hz, 1H), 7.30-7.32 (m, 1H), 7.35-7.43 (m, 2H), 7.56-7.69 (m, 2H), 7.92 (dd, J=7.45, 0.88 Hz, 1H), 8.47 (br s, 1H), 11.12 (br s, 1H), 12.55-12.72 (m, 1H). ESI-MS m/z [M+H]+ calc'd for C23H24N8O2, 445.20. found 445.3.

Reference： [1]Patent: US2012/220575,2012,A1 .Location in patent: Page/Page column 62-63

5
[ 840491-78-3 ]
[ 37599-58-9 ]
[ 1417790-18-1 ]

Reference： [1]Journal of Medicinal Chemistry,2013,vol. 56,p. 568 - 583

6
[ 32315-10-9 ]
[ 7019-01-4 ]
[ 37599-58-9 ]
[ 1363131-75-2 ]

Reference： [1]Journal of Medicinal Chemistry,2013,vol. 56,p. 4921 - 4937

7
[ 37599-58-9 ]
[ 1513-87-7 ]
[ 1487874-64-5 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine In acetonitrile at 75℃; for 2h; Sealed tube; Combinatorial reaction / High throughput screening (HTS);

Reference： [1]Bogolubsky, Andrey V.; Moroz, Yurii S.; Mykhailiuk, Pavel K.; Granat, Dmitry S.; Pipko, Sergey E.; Konovets, Anzhelika I.; Doroschuk, Roman; Tolmachev, Andrey [ACS Combinatorial Science, 2014, vol. 16, # 6, p. 303 - 308]

8
[ 1072804-20-6 ]
[ 37599-58-9 ]
[ 1072804-34-2 ]

Yield	Reaction Conditions	Operation in experiment
31%		General procedure: 5.1.5 2-(1-(4-Fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide (7a) To a solution of 6a (2.00 g, 5.98 mmol), EDCI (1.50 g, 7.82 mmol) and iPr2NEt (2.67 mL, 15.64 mmol) in N,N-dimethylformamide (80 mL) was added HOBt (1.00 g, 7.40 mmol). The reaction mixture was stirred at ambient temperature for 15 min, followed by addition of 3-(aminomethyl)pyridine (0.73 mL, 7.16 mmol). After stirring for 17 h at ambient temperature, the reaction mixture was diluted with ethyl acetate (300 mL) and sequentially washed with water, saturated NaHCO3 solution, water and brine. The organic solution was dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated in vacuo, and the residue was crystallized from ethyl acetate and hexanes to yield 7a as an off-white solid (1.93 g, 76%), mp 178-180 C (ethyl acetate/hexanes); By a similar procedure as described for 7a, 7j was obtained as an off-white solid (1.77g, 31%). Mp 181-182C (ethyl acetate); 1H NMR (300MHz, DMSO-d6) delta 12.63 (br s, 1H), 8.76-8.72 (m, 2H), 7.62 (s, 1H), 7.41-7.36 (m, 2H), 7.22-7.17 (m, 2H), 6.17 (d, J=1.8Hz, 1H), 5.00 (s, 2H), 4.42 (d, J=5.6Hz, 2H), 2.56 (s, 3H); 13C NMR (75MHz, DMSO-d6) delta 161.7 (d, JCF=244Hz), 160.8, 151.3, 150.7, 149.7, 132.2 (d, JCF=3Hz), 132.1, 130.0 (d, JCF=8Hz), 129.1, 122.8, 115.4 (d, JCF=22Hz), 103.1, 47.7, 37.1, 16.9; MS (ES+) m/z 413.8 (M+1); Anal. Calcd for C18H16FN7O2S: C, 52.29; H, 3.90; N, 23.72. Found: C, 51.78; H, 3.94; N, 23.23.

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 455 - 465

9
[ 37599-58-9 ]
(E)-1H-Pyrazole-3-carbxaldehyde oxime [ No CAS ]

Reference： [1]Advanced Synthesis and Catalysis,2015,vol. 357,p. 1175 - 1180

10
[ 67869-90-3 ]
[ 37599-58-9 ]
(E)-N-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methylene)-1-(1H-pyrazol-3-yl)methanamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
89%	at 20℃;	General procedure: Compound 1 (535 mg, 3.00 mmol, 1 equiv.)was dissolved in MeOH (3 mL). The corresponding amine(3.6 mmol) was added. The reaction mixture was stirred at RT for overnight. The solvent was removed under reduced pressure. The residue was purified by column chromatography(neutral Al2O3, EtOAc/hexane) to give pure compound 2.

Reference： [1]Chemical and Pharmaceutical Bulletin,2017,vol. 65,p. 178 - 185

11
4-fluoro-2-hydroxy-5-(N-(4-isopropoxyphenyl)sulfamoyl)benzamide [ No CAS ]
[ 37599-58-9 ]
4-(((1H-pyrazol-3-yl)methyl)amino)-2-hydroxy-5-(N-(4-isopropoxyphenyl)sulfamoyl)benzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
52 mg	In butan-1-ol; at 110 - 140℃; for 14h;Microwave irradiation;	A 5 mL microwave reaction vial equipped with a stirbar was charged with 4-fluoro-2- hydroxy-5-(N-(4-isopropoxyphenyl)sulfamoyl)benzamide (Example 107, 0.250 gl) and (1 H-pyrazol-3-yl)methanamine (0.198 g). The solids were taken up in 1 -butanol (3.4 mL) and the resulting reaction mixture was subjected to microwave irradiation at 1 10 C with stirring on high absorption setting for 2 sessions of 2 h each for a total of 4 h reaction time. The reaction mixture was resubjected to microwave irradiation at 140 C with stirring for an additional 2 sessions of 2 h and 8 h (14 h total microwave reaction time). The mixture was then cooled to room temperature, diluted with ethanol to ~20 mL total volume, filtered, and concentrated to a residue. The residue was taken up in a minimum amount of DMSO for purification by reverse phase silica gel using a 30 gram RediSep Gold C18 reverse phase silica cartridge (0-90% acetonitrile in 0.2M aq ammonium acetate). Fractions containing the desired material were pooled and then concentrated to remove the acetonitrile. The aqueous layer was acidified to ~pH 4.5 by addition of 1 N aq hydrochloric acid. The mixture was extracted twice with ethyl acetate and the organic layers were pooled, dried over sodium sulfate, filtered, and concentrated to dryness. The solid mass was triturated with diethyl ether to afford the title compound as an off-white solid (52 mg. LCMS m/z 446.3 (M+H)+. 1H NMR (400 MHz, DMSO-c/6) delta ppm 1 .13 - 1 .23 (m, 6 H) 4.38 (d, J=5.58 Hz, 2 H) 4.47 (spt, J=6.04 Hz, 1 H) 6.13 (s, 1 H) 6.16 (d, J=2.03 Hz, 1 H) 6.63 - 6.81 (m, 3 H) 6.89 - 7.01 (m, 2 H) 7.62 (br. s., 2 H) 8.06 (s, 1 H) 8.27 (br. s., 1 H) 9.81 (br. s., 1 H) 12.52 (br. s., 1 H) 13.74 (br. s., 1 H).

Reference： [1]Patent: WO2017/153952,2017,A1 .Location in patent: Page/Page column 218; 219

12
[ 1513-87-7 ]
[ 37599-58-9 ]
C₇H₈F₃N₃O₂ [ No CAS ]

Reference： [1]ACS Combinatorial Science,2018,vol. 20,p. 35 - 43

13
[ 1268618-51-4 ]
[ 37599-58-9 ]
N2-(3-((5-(2-((((1H-pyrazol-3-yl)methyl)amino)methyl)phenyl)-2,3-dihydrobenzofuran)-7-sulfonamido)thiophene-2-carbonyl)-Nω-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-L-arginine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 4135 - 4154

14
[ 1268618-50-3 ]
[ 37599-58-9 ]
N2-(3-((5-(3-((((1H-pyrazol-3-yl)methyl)amino)methyl)phenyl)-2,3-dihydrobenzofuran)-7-sulfonamido)thiophene-2-carbonyl)-Nω-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-L-arginine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 4135 - 4154

15
[4-(2-pyridin-4-ylbenzenesulfonyl)phenyl]carbamic acid phenyl ester [ No CAS ]
[ 37599-58-9 ]
1-(1H-pyrazol-4-ylmethyl)-3-[4-(2-pyridin-4-ylbenzenesulfonyl)phenyl]urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
21%	With triethylamine; In acetonitrile; at 80℃; for 2h;	To a solution of [4-(2-pyridin-4-yl-benzenesulfonyl)-phenyl]-carbamic acid phenyl ester (100 mg, 0.23 mmol) in ACN (10 mL) was added <strong>[37599-58-9](1H-pyrazol-3-yl)methanamine</strong> (27.1 mg, 0.28 mmol) and TEA (47.1 mg, 0.47 mmol). Then the mixture was stirred at 80 C for 2 hrs. This reaction was monitored by LCMS. The reaction mixture was then diluted with H20 (10 mL) and extracted with EA (10 mL x3) The combined organic layer was dried over anhydrous Na2SO4, and evaporated in vacuum. The residue was purified by prep-HPLC to give 1-(1H-pyrazol-4-ylmethyl)-3- [4-(2-pyridin-4-yl-benzenesulfonyl)-phenyl]-urea (21.3 mg, 21%) as a yellow solid. ?H NIVIR (400 IVIHz, DMSO-d6): oe = 8.43-8.41 (m, 2H), 8.34-8.32 (m, 1H), 7.72-7.69 (m, 2H), 7.58 (s, 2H), 7.36- 7.34 (m, 2H), 7.27-7.25 (m, 1H), 7.18-7.15 (m, 2H), 7.08-7.07 (m, 2H), 4.28 (s, 2H). MS: m/z 433.8 (M+H).

Reference： [1]Patent: WO2018/132372,2018,A1 .Location in patent: Paragraph 01084

16
[4-(1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-carbamic acid phenyl ester [ No CAS ]
[ 37599-58-9 ]
1-[4-(1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-3-(1H-pyrazol-4-ylmethyl)urea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
3.1%	With triethylamine; In acetonitrile; at 80℃;	To a solution of [4-(1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-carbamic acid phenyl ester (120 mg, 0.35 mmol) in ACN (10 mL) was added <strong>[37599-58-9](1H-pyrazol-3-yl)methanamine</strong> (55.7 mg, 0.42 mmol) and TEA (85 mg, 0.84 mmol). Then the mixture was stirred at 80 C overnight. This reaction was monitored by LC-MS. The reaction mixture was then diluted with H20 (10 mL) and extracted with EA (10 mLx3). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated in vacuum. The residue was purified by pre-HPLC to give 1-[4-(1-methyl-1H- pyrazolo [4,3 -c]pyridin-3 -yl)-phenyl] -3 -(1 H-pyrazol-4-ylmethyl)-urea (3.8 mg, 3.1%) as a yellow solid. ?H NMR (400 IVIHz, DMSO-d6): oe = 9.26 (d, J= 0.8 Hz, 1H), 8.36 (d, J= 6.0 Hz, 1H), 7.91 (d, J= 9.2 Hz, 2H), 7.61-7.56 (m, 5H), 4.32 (s, 2H), 4.12 (s, 3H). MS: m/z 348.1 (M+H).

Reference： [1]Patent: WO2018/132372,2018,A1 .Location in patent: Paragraph 01247

17
ethyl 4-((phenoxycarbonyl)amino)benzoate [ No CAS ]
[ 37599-58-9 ]
ethyl 4-(3-((1H-pyrazol-3-yl)methyl)ureido)benzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
12%	With N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; at 90℃;	To a solution of C-(1H-pyrazol-3 -yl)-methylamine (81.5 mg, 0.84 mmol) in dioxane (30 mL) was added 4-phenoxycarbonylamino-benzoic acid ethyl ester (200 mg, 0.7 mmol) and DIPEA (181 mg, 1.4 mmol). After stirred at 90 C overnight, the reaction mixture was concentrated in vacuum. The residue was purified by pre-HPLC to afford ethyl 4-(3-((1H-pyrazol-3- yl)methyl)ureido)benzoate (25 mg, 12%) as a white solid. ?H NIVIR (400 IVIHz, CD3OD): oe = 7.91 (d, J= 8.8 Hz, 2H), 7.57 (s, 1H), 7.49 (d, J= 8.4 Hz, 2H), 6.29 (s, 1H), 4.43 (s, 2H), 4.32 (q, J 7.2 Hz, 2H), 1.37 (t, J= 7.2 Hz, 3H). MS: m/z 289.0 (M+H).

Reference： [1]Patent: WO2018/132372,2018,A1 .Location in patent: Paragraph 00398

18
4-chloro-7-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)quinolin-2-amine [ No CAS ]
[ 37599-58-9 ]
N₄-((1H-pyrazol-3-yl)methyl)-7-(1H-pyrazol-5-yl)quinoline-2,4-diamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
24.7%		To a solution of 4-chloro-7-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl)quinolin-2-amine (20 mg, 0.061 mmol) and (lH-pyrazol-3-yl)methanamine (59.1 mg, 0.608 mmol) in DMSO (0.5 mL) was added Hunig's Base (0.032 mL, 0.182 mmol). The reaction was heated to 120 C overnight. The reaction was cooled, diluted with water, and extracted three times with EtOAc. The organic layers were concentrated, then dissolved in 0.4 mL DCM and 0.4 mL TFA. After 1 hour, the reaction was complete by LCMS. The reaction was concentrated and azeotroped with DCM. The residue was dissolved in DMF, filtered through a syringe filter, and the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 200 mm x 19 mm, 5-muiotatauiota particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1%trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 0% B, 0-40% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-mupiiota particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 3- minute hold at 0% B, 0-32% B over 25 minutes, then a 5-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give N4-((lH-pyrazol-3-yl)methyl)-7-(lH-pyrazol-5-yl)quinoline-2,4- diamine (4.6 mg, 24.7%). NMR (500 MHz, DMSO-de) delta 8.00 (br d, J=8.2 Hz, 1H),7.75 (s, 1H), 7.72 (br s, 1H), 7.58 (br s, 1H), 7.54 (br d, J=7.9 Hz, 1H), 7.43 (br s, 1H),6.76 (s, 1H), 6.62 - 6.41 (m, 1H), 6.20 (s, 1H), 5.76 (s, 1H), 4.42 (br d, J=5.2 Hz, 2H). LC RT: 0.99 min. M/Z= 306.18. (1550)

Reference： [1]Patent: WO2019/14402,2019,A1 .Location in patent: Page/Page column 151; 153

19
[ 728034-12-6 ]
[ 37599-58-9 ]
[ 165806-95-1 ]
4-(1-((1H-pyrazol-3-yl)methyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
39%		General procedure: To a solutionof the corresponding aldehyde (1.2 eq.; unless stated otherwise) in DMF (2 inL per 0.3 mmol of aldehyde; unless stated otherwise) was added the corresponding amine (2.5 eq.; unless stated otherwise) and the resulting solution was stirred at 25 C to form the corresponding inline. Then, the corresponding isocyano(tosyl)methyl)arene reagent (1 eq.; unless stated otherwise) and K2CO3 (1.5 eq.; unless stated otherwise) were added and the reaction mixture was stirred at 25 C (unless stated otherwise). The reaction was stopped after the time indicated for each particular reaction. The reaction progress was monitored by TLC. (0083) A saturated aqueous solution of NH4CI (10 mL per 1 mmol of aldehyde) was added to the reaction mixture, which was then extracted with EtOAc (2 x 30 mL per 1 mmol of aldehyde). The combined organic extracts were washed with H2O (2 x 25 mL per 1 mmol of aldehyde), dried over MgSCC, filtered, and the solvent was evaporated in vacuo to provide the crude product. The residue obtained after the workup was purified using column chromatography or preparative TLC (unless stated otherwise). (0084) note: in cases when the amine was used as HC1 salt, 4 eq. of K2CO3 were used

Reference： [1]Patent: WO2019/185631,2019,A1 .Location in patent: Page/Page column 14; 82

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 37599-58-9 ]

Amines

[ 612511-81-6 ]

(1-Methyl-1H-pyrazol-3-yl)methanamine

Similarity: 0.85

[ 33064-36-7 ]

1H-Pyrazole-3-carboxamide

Similarity: 0.78

[ 64517-88-0 ]

1,3-Dimethyl-1H-pyrazol-4-amine

Similarity: 0.74

[ 197367-87-6 ]

1,3-Dimethyl-1H-pyrazol-4-amine dihydrochloride

Similarity: 0.72

[ 268724-49-8 ]

3-Methyl-1H-pyrazol-5-amine

Similarity: 0.71

Related Parent Nucleus of
[ 37599-58-9 ]

Pyrazoles

[ 612511-81-6 ]

(1-Methyl-1H-pyrazol-3-yl)methanamine

Similarity: 0.85

[ 1453-58-3 ]

3-Methylpyrazole

Similarity: 0.83

[ 33064-36-7 ]

1H-Pyrazole-3-carboxamide

Similarity: 0.78

[ 64517-88-0 ]

1,3-Dimethyl-1H-pyrazol-4-amine

Similarity: 0.74

[ 3920-50-1 ]

Pyrazole-3-carboxaldehyde

Similarity: 0.73

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 37599-58-9 ] {[proInfo.proName]}

Quality Control of [ 37599-58-9 ]

Related Doc. of [ 37599-58-9 ]

Product Details of [ 37599-58-9 ]

Calculated chemistry of [ 37599-58-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 37599-58-9 ]

Application In Synthesis of [ 37599-58-9 ]

[ 37599-58-9 ] Synthesis Path-Upstream 1~1

[ 37599-58-9 ] Synthesis Path-Downstream 1~19

Related Functional Groups of [ 37599-58-9 ]

Amines

Related Parent Nucleus of [ 37599-58-9 ]

Pyrazoles

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 37599-58-9 ]

Related Parent Nucleus of
[ 37599-58-9 ]